nice to wake up on a Sunday and see that Motley Fool featured Vical's 31% price move, triggered by Vijay's presentation on Wednesday. I like free PR like this. Let's see if we've finally punched through the $3.75 wall that this MB has seen in this movie before. IMO we'll continue moving higher this month. Time will tell.
If A-7 is approved, I think VICL will be bought, and I think it is worth much more to BMY than medarex was, even with MDX1106 in the pipeline. I think $2.4 would be the lowest tolerable price if A-7 hits, double that? We know that their basic technology works and is marketable, that is what Oncept means. A-7 working would mean that they have a viable platform for human gene therapy, as well as one worth while drug. They must have tons of propitiatory IP that is worth a mountain of cash and future revenues. All this hinges on A-7 working due to its proof of principle quality. I have a feeling that A-7 will beat both Yervoy and MDX1106 on several metrics, the only thing I can think of that would make this not true would be some kind of fraud, the last we have heard is that the event threshold has not yet been met.